Literature DB >> 31215970

Use of Cardiac Resynchronization Therapy Defibrillator in US Hospitals.

Amneet Sandhu1,2, Haikun Bao3, Karl E Minges3, Paul D Varosy1,2, Ryan T Borne1, Mathew M Zipse1, Lucas Marzec4, Pamela Peterson1,5, Frederick Masoudi1, Steven M Bradley6,7.   

Abstract

Importance: Cardiac resynchronization therapy (CRT) provides significant reduction in morbidity and mortality in select patients with left ventricular systolic dysfunction and specific parameters of electrocardiographic evidence of dyssynchrony. Relative to the 2012 American College of Cardiology/American Heart Association/Heart Rhythm Society guideline update for patient selection, little is known about the contemporary use of CRT in the United States. Objective: To describe the use of CRT defibrillator (CRT-D) in the period around guideline revision. Design, Setting, and Participants: All patients undergoing new CRT-D implantations in the National Cardiovascular Data Registry for implantable cardioverter-defibrillators from January 1, 2012, to December 31, 2015, at 1710 participating hospitals were identified for this population-based study. Rates of CRT-D implantation that were concordant and discordant with the 2012 American College of Cardiology/American Heart Association/Heart Rhythm Society update of the 2008 guidelines for device-based therapy were determined. Analysis began in January 2012. Main Outcomes and Measures: Increase in guideline-concordant CRT-D implantation.
Results: Among 135 253 patients undergoing initial CRT-D implantation, 88 923 were included in the study cohort, of which 73 859 implants (83.1%) were guideline concordant. The proportion of guideline-concordant devices increased from 81.2% (16 710 of 20 481) in 2012 to 84.2% (20 515 of 24 356) in 2015 (P for trend < .001). Significant clustering was noted with 33% (565 of 1710) of hospitals accounting for greater than 70% (10 545 of 15 065) of guideline-discordant CRT-D implants. Conduction abnormalities, in particular, underlying right bundle branch block (3597 [23.9%] vs 7425 [10.1%]; P < .001) and nonspecific intraventricular conduction delay (3341 [22.2%] vs 4769 [6.5%]; P < .001) were more common in those who received guideline-discordant devices. Conclusions and Relevance: Rates of guideline-concordant CRT-D implantation increased during the study. The major fraction of guideline-discordant implants were clustered at a minority of hospitals. Conduction abnormalities, particularly non-left bundle branch block and nonspecific intraventricular conduction delay, correlated with guideline-discordant implants indicating continued opportunity for dissemination and understanding of guideline updates.

Entities:  

Mesh:

Year:  2019        PMID: 31215970      PMCID: PMC6584888          DOI: 10.1001/jamacardio.2019.1755

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  16 in total

1.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

2.  Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients.

Authors:  Kenneth C Bilchick; Sandeep Kamath; John P DiMarco; George J Stukenborg
Journal:  Circulation       Date:  2010-11-01       Impact factor: 29.690

3.  Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials.

Authors:  Ilke Sipahi; Thomas P Carrigan; Douglas Y Rowland; Bruce S Stambler; James C Fang
Journal:  Arch Intern Med       Date:  2011-06-13

4.  The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012.

Authors:  John C Messenger; Kalon K L Ho; Christopher H Young; Lara E Slattery; Jasmine C Draoui; Jeptha P Curtis; Gregory J Dehmer; Frederick L Grover; Michael J Mirro; Matthew R Reynolds; Ivan C Rokos; John A Spertus; Tracy Y Wang; Stuart A Winston; John S Rumsfeld; Frederick A Masoudi
Journal:  J Am Coll Cardiol       Date:  2012-09-19       Impact factor: 24.094

5.  2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Andrew E Epstein; John P DiMarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney; Cynthia M Tracy; Andrew E Epstein; Dawood Darbar; John P DiMarco; Sandra B Dunbar; N A Mark Estes; T Bruce Ferguson; Stephen C Hammill; Pamela E Karasik; Mark S Link; Joseph E Marine; Mark H Schoenfeld; Amit J Shanker; Michael J Silka; Lynne Warner Stevenson; William G Stevenson; Paul D Varosy
Journal:  J Am Coll Cardiol       Date:  2012-12-19       Impact factor: 24.094

6.  Clinical and electrocardiographic predictors of a positive response to cardiac resynchronization therapy in advanced heart failure.

Authors:  Guillaume Lecoq; Christophe Leclercq; Emmanuelle Leray; Christophe Crocq; Christine Alonso; Christian de Place; Philippe Mabo; Claude Daubert
Journal:  Eur Heart J       Date:  2005-02-23       Impact factor: 29.983

7.  The NCDR ICD Registry: A Foundation for Quality Improvement.

Authors:  Frederick M Masoudi; William J Oetgen
Journal:  J Am Coll Cardiol       Date:  2017-09-05       Impact factor: 24.094

8.  Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT).

Authors:  Wojciech Zareba; Helmut Klein; Iwona Cygankiewicz; W Jackson Hall; Scott McNitt; Mary Brown; David Cannom; James P Daubert; Michael Eldar; Michael R Gold; Jeffrey J Goldberger; Ilan Goldenberg; Edgar Lichstein; Heinz Pitschner; Mayer Rashtian; Scott Solomon; Sami Viskin; Paul Wang; Arthur J Moss
Journal:  Circulation       Date:  2011-02-28       Impact factor: 29.690

9.  Prevalence and predictors of off-label use of cardiac resynchronization therapy in patients enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry.

Authors:  Adam S Fein; Yongfei Wang; Jeptha P Curtis; Frederick A Masoudi; Paul D Varosy; Matthew R Reynolds
Journal:  J Am Coll Cardiol       Date:  2010-08-31       Impact factor: 24.094

10.  Geographic and Temporal Variation in Cardiac Implanted Electric Devices to Treat Heart Failure.

Authors:  Laura A Hatfield; Daniel B Kramer; Rita Volya; Matthew R Reynolds; Sharon-Lise T Normand
Journal:  J Am Heart Assoc       Date:  2016-07-28       Impact factor: 5.501

View more
  2 in total

1.  Risk factors for ventricular tachyarrhythmic events in patients without left bundle branch block who receive cardiac resynchronization therapy.

Authors:  Arwa Younis; Mehmet K Aktas; Wojciech Zareba; Scott McNitt; Valentina Kutyifa; Ilan Goldenberg
Journal:  Ann Noninvasive Electrocardiol       Date:  2021-03-27       Impact factor: 1.468

2.  Temporal trends and long-term outcomes among recipients of cardiac resynchronization therapy with defibrillator in the United States, 2011-2015: Insights from the National Cardiovascular Data Registry.

Authors:  Douglas Darden; Pamela N Peterson; Xin Xin; Muhammad Bilal Munir; Karl E Minges; Ilan Goldenberg; Jeanne E Poole; Gregory K Feld; Ulrika Birgersdotter-Green; Jeptha P Curtis; Jonathan C Hsu
Journal:  Heart Rhythm O2       Date:  2022-04-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.